ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1595

Using Rheumatoid Arthritis Communication Tool Developed by the RISE Learning Collaborative to Promote Shared Decision-Making

Joad Eseddi1, Puneet Bajaj2, Gabriela Schmajuk3, Jinoos Yazdany4 and Salahuddin Kazi5, 1UT Southwestern Medical Center, Dallas, TX, 2UT Southwestern, Dallas, TX, 3University of California, San Francisco, Atherton, CA, 4University of California, San Francisco, San Francisco, CA, 5Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX

Meeting: ACR Convergence 2020

Keywords: Decision analysis, Disease Activity, Measurement Instrument, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Measures & Measurement of Healthcare Quality Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient care is moving from physician directed treatment to a co-design framework that focuses on creating a partnership between patients and physicians. This new framework is centered on patients’ values, with the aim of enhancing care by improving mutual understanding, goal alignment and patient-physician shared decision making (SDM). Our objective was to implement and evaluate the impact of a Rheumatoid Arthritis (RA) SDM tool, with the goal of improving SDM between RA patients and their providers.

Methods: A vital component to effectively improve outcomes in RA patients is by establishing personalized treatment plans and targets through SDM. An SDM tool (Figure 1) developed by the RISE Learning Collaborative (RISE-LC), a learning network established in March 2019 to coordinate quality improvement (QI) efforts in adult rheumatology practices across multiple centers, was introduced into our academic rheumatology clinic workflow (Figure 2) in January 2020.

We conducted a retrospective chart review of 99 patients: 50 of them with visits in September – December, prior to implementation of the SDM tool and 49 of them with a visit between January-March 2020, following tool implementation. The patients in each group categorized based on their CDAI scores: Remission: 0-2.8, Low disease activity (LDA): 2.9–10, Low-moderate disease activity (LMDA): 10.1–16, high-moderate disease activity (HMDA): 16.1–22 and high disease activity (HDA): >22. We used Minitab (Version 19.2020.1) for statistical analysis, and used two-sample t-test and two-proportion test to compare the 2 cohorts’ demographics, goals for the visit, CDAI scores, number of medications patients were on, number of associated co-morbidities and whether patients had a change in therapy.

Results: 89.9% (89/99) of the included patients were females (see Table 1). Among the patients who used the SDM tool, 65.3% used less than 2 lines to answer the question ‘what’s on my mind for today’s visit?’. Having less pain was the most common goal (65.3%) overall and this did not vary with the level of disease activity. The second most common goal was to avoid medication side effects (40.8%), which was listed more frequently for patients in LDA (47.3% or 9/19) and LMDA (50% or 6/12) groups. The patients who had a change in therapy in the non-SDM cohort were younger and had higher CDAI scores. Comparing other parameters did not reach statistical significance. See Table 1

Conclusion: Implementation of a SDM tool was feasible in our practice. Analysis of SDM tool content revealed that most patients had focused goals; less pain was the most common goal followed by having fewer medication side effects. As the disease activity increased, patients were willing to make changes to therapy. No early differences in treatment escalation were seen among those using the SDM tool, but larger studies are ongoing to assess the impact of tool implementation. Next steps also include incorporating SDM tool components into a rheumatology dashboard in our electronic health record.

Figure 1: SDM Tool

Figure 2: UT Southwestern Rheumatology Clinic Workflow

Table 1: Comparing SDM Tool Cohort With Non-SDM Tool Cohort


Disclosure: J. Eseddi, None; P. Bajaj, None; G. Schmajuk, None; J. Yazdany, Eli Lilly, 1, Astra Zeneca, 1; S. Kazi, ABIM, 1, Regeneron, 1, Sanofi, 1.

To cite this abstract in AMA style:

Eseddi J, Bajaj P, Schmajuk G, Yazdany J, Kazi S. Using Rheumatoid Arthritis Communication Tool Developed by the RISE Learning Collaborative to Promote Shared Decision-Making [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/using-rheumatoid-arthritis-communication-tool-developed-by-the-rise-learning-collaborative-to-promote-shared-decision-making/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-rheumatoid-arthritis-communication-tool-developed-by-the-rise-learning-collaborative-to-promote-shared-decision-making/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology